Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 41
1979 92
1980 70
1981 87
1982 147
1983 116
1984 103
1985 130
1986 205
1987 170
1988 140
1989 266
1990 227
1991 171
1992 252
1993 192
1994 245
1995 174
1996 207
1997 178
1998 157
1999 179
2000 165
2001 198
2002 171
2003 209
2004 217
2005 317
2006 353
2007 398
2008 439
2009 446
2010 488
2011 474
2012 357
2013 377
2014 337
2015 327
2016 315
2017 306
2018 288
2019 305
2020 139
Text availability
Article attribute
Article type
Publication date

Search Results

8,489 results
Results by year
Filters applied: . Clear all
Page 1
Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239-1247.
Eichbaum M, Eichbaum C. Eichbaum M, et al. Cancer Chemother Pharmacol. 2018 Dec;82(6):1087-1088. doi: 10.1007/s00280-018-3589-5. Epub 2018 Apr 25. Cancer Chemother Pharmacol. 2018. PMID: 29696361 No abstract available.
Cancer immunotherapy: the art of targeting the tumor immune microenvironment.
da Silva JL, Dos Santos ALS, Nunes NCC, de Moraes Lino da Silva F, Ferreira CGM, de Melo AC. da Silva JL, et al. Cancer Chemother Pharmacol. 2019 Aug;84(2):227-240. doi: 10.1007/s00280-019-03894-3. Epub 2019 Jun 25. Cancer Chemother Pharmacol. 2019. PMID: 31240384 Review.
Autophagy modulation: a prudent approach in cancer treatment?
Bishop E, Bradshaw TD. Bishop E, et al. Cancer Chemother Pharmacol. 2018 Dec;82(6):913-922. doi: 10.1007/s00280-018-3669-6. Epub 2018 Sep 4. Cancer Chemother Pharmacol. 2018. PMID: 30182146 Free PMC article. Review.
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial.
Esteva FJ, Baranau YV, Baryash V, Manikhas A, Moiseyenko V, Dzagnidze G, Zhavrid E, Boliukh D, Stroyakovskiy D, Pikiel J, Eniu AE, Li RK, Rusyn AV, Tiangco B, Lee SJ, Lee SY, Yu SY, Stebbing J. Esteva FJ, et al. Cancer Chemother Pharmacol. 2019 Oct;84(4):839-847. doi: 10.1007/s00280-019-03920-4. Epub 2019 Aug 19. Cancer Chemother Pharmacol. 2019. PMID: 31428820 Free PMC article. Clinical Trial.
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, Trojan J, Kozloff M, Simionato F, Cleverly A, Smith C, Wang S, Man M, Driscoll KE, Estrem ST, Lahn MMF, Benhadji KA, Tabernero J. Melisi D, et al. Cancer Chemother Pharmacol. 2019 May;83(5):975-991. doi: 10.1007/s00280-019-03807-4. Epub 2019 Mar 18. Cancer Chemother Pharmacol. 2019. PMID: 30887178 Clinical Trial.
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Mouri A, Kaira K, Yamaguchi O, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Mouri A, et al. Cancer Chemother Pharmacol. 2019 Oct;84(4):873-880. doi: 10.1007/s00280-019-03926-y. Epub 2019 Aug 23. Cancer Chemother Pharmacol. 2019. PMID: 31444618
8,489 results
Jump to page
Feedback